A Randomized, Open Label, Phase II Study on Safety and Efficacy of Long Term Treatment of ICL670 Relative to Deferoxamine in Sickle Cell Disease Patients With Transfusional Hemosiderosis

Trial Profile

A Randomized, Open Label, Phase II Study on Safety and Efficacy of Long Term Treatment of ICL670 Relative to Deferoxamine in Sickle Cell Disease Patients With Transfusional Hemosiderosis

Completed
Phase of Trial: Phase II

Latest Information Update: 24 Aug 2017

At a glance

  • Drugs Deferasirox (Primary) ; Deferasirox
  • Indications Sickle cell anaemia
  • Focus Adverse reactions
  • Sponsors Novartis Pharmaceuticals Corporation
  • Most Recent Events

    • 25 Jun 2017 Results (n=282) of retrospective analysis in subgroups of Italian patients assessing serum creatinine using patient data from the registration studies (studies 105, 106 and CICL670 0107, CICL670A0108, CICL670A0109), presented at the 22nd Congress of the European Haematology Association
    • 05 Sep 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top